COMP <GO>
INSP vs JNJ // ENTERPRISE SCALE & MARKET CAP
Inspire Medical Systems Inc. (NYSE) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: INSP 5
— JNJ 7
▲ ENTERPRISE SCALE & MARKET CAP LEADER: JNJ
LAST: $71.18 (+0.30%) • MKT CAP: $2.06B
market-cap
$2.06B
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
market-cap
$662.49B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (INSP VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | INSP | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 85.40% | 67.90% | +17.50 | INSP | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.00% | 25.50% | -19.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | 23.3x | 18.5x | +4.80 | JNJ | /valuation <GO> |
| Free Cash Flow Yield | 3.81% | 2.97% | +0.84 | INSP | /fcf-yield <GO> |
| Operating Margin | 5.60% | 34.70% | -29.10 | JNJ | /operating-margins <GO> |
| Net Profit Margin | 15.90% | 28.50% | -12.60 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 13.60% | 6.00% | +7.60 | INSP | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 11.40 | 5.59 | +5.81 | INSP | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.5 | 62.1 | -8.60 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.9x | 23.0x | -11.10 | INSP | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $2.06B | $662.49B | -$660.43B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | INSP REV | JNJ REV | INSP GROSS % | JNJ GROSS % | INSP FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $912.0M | $94.19B | 85.4% | 67.9% | $78.5M | $19.70B |
| FY 2024 | $802.8M | $88.82B | 84.7% | 69.1% | $91.1M | $19.84B |
| FY 2023 | $624.8M | $85.16B | — | — | $24.7M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
INSP // BETA —
JNJ // BETA 1.08